U.S., April 10 -- ClinicalTrials.gov registry received information related to the study (NCT07521007) titled 'A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis' on April 02.
Brief Summary: This study is designed to evaluate the efficacy and safety of intravenously administered YN001 in patients diagnosed with coronary atherosclerosis, who are receiving background therapy for cardiovascular (CV) risk factors management.
Study Start Date: April 30
Study Type: INTERVENTIONAL
Condition:
Atherosclerosis
Coronary Artery Disease
Intervention:
DRUG: YN001/Placebo 40mg
Dose 1 YN001/Placebo 40mg will be administrated on Day 1 of each week from Week 1 to Week 13, 13 times in total.
DRUG: YN001/Placebo 20mg
YN001/Plac...